Proliferative Diabetic Retinopathy Market to Each Roughly US$ 1,000 Million by 2026-end: Transparency Market Research

Monday, March 19, 2018 Diabetes News
Email Print This Page Comment bookmark
Font : A-A+

ALBANY, New York, March 19, 2018 /PRNewswire/ --

According to World Health Organization, number of people affected

with diabetes has exceeded 400 Mn, in case of adults, in 2014. Additionally, global prevalence of diabetes doubled, rising at over 8% in adult population. The Department of Assistive and Rehabilitative Services (DARS) has reported that nearly 80% of
the diabetic population was affected from diabetic retinopathy in 2013, with a notable portion of this percentile estimated to acquire the proliferative condition. These numbers are further poised to witness a rise in the years to come, driven by unhealthy consumption patterns and comfort-driven lifestyles of consumers worldwide. This will further have a robust impact on demand for treatment drugs apropos to proliferative diabetic retinopathy in the foreseeable future.

The report estimates the market to record a splendid rise over the forecast period 2017 to 2026. Nearly US$ 1,000 Mn worth of drugs for treatment of proliferative diabetic retinopathy are anticipated to be sold worldwide by 2026-end. Considered as a serious sight threatening ailment on account of long-term exposure to diabetes, diabetic retinopathy results into progressive retinal damage and affects retinal circulatory system. Extremity of the disease, which may lead to proliferative condition, determines the selection of effective therapeutic measure, thereby entailing requirement for intraocular injections, laser surgery, vitrectomy, or anti-VEGF drug prescriptions.

Get PDF Brochure for Research Insights at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40637

North America to Stay at Forefront of Global Proliferative Diabetic Retinopathy Market 

In terms of revenues, North America is likely to remain at the forefront of the global proliferative diabetic retinopathy, driven by supportive reimbursement policies offered by the government coupled with greater prevalence of diabetes in the region. Additionally, robust penetration of management drugs such as anti-VEGF drugs viz. Lucentis, Avastin, and Eylea, has further supported revenue generation from treatment of this disease in North America. Europe and Asia-Pacific excluding Japan are also likely to endure as significant revenue contributors to the global proliferative diabetic retinopathy market.

Request a Custom Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=40637

Anti-VEGF drugs are likely to remain preferred among various drug class utilized for treatment of proliferative diabetic retinopathy across the globe. Revenues from sales of anti-VEGF drugs are poised to reach approximately US$ 700 Mn by 2026-end. Although corticosteroids' sales are expected to record an impressive expansion in the market, revenues from this drug class will continue to be sluggish.

Key Research Findings from TMR's Report 

  • Albeit injectables will account for relatively larger market revenue share based on mode of administration, revenues from oral mode of administration of drugs for treating proliferative diabetic retinopathy will increase at the highest CAGR through 2026
  • Retail pharmacies will persist as fast-expanding distribution channel for proliferative diabetic retinopathy treatment drugs

Companies in the global proliferative diabetic retinopathy market are employing strategic initiatives that include product development, geographical expansion, acquisitions, and mergers. These strategies are likely to aid the market players in advancing their businesses and increasing their market footprint. For example, ThromboGenics initiated partnership with Novartis (Alcon) for assisting in commercialization and marketing activities of JETREA beyond the U.S.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40637

On similar lines, Alimera initiated sales of ILLUVEN in the U.K. and Germany, in a bid to foray the European market. The initiative was primarily aimed at tapping new markets and boosting revenue generation of the company. A new report of Transparency Market Research has profiles key players making notable contribution to expansion of the global market for proliferative diabetic retinopathy, which include Pfizer, Inc., Genentech, Inc. (Roche Holdings), Merck KGaA, Allergan Plc, Santen Pharmaceutical Co., Ltd., Cipla, Ltd., Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Intas Pharmaceuticals Limited, and Novartis AG.

Popular Research Reports by TMR: 

  • Diabetic Neuropathy Market:    https://www.transparencymarketresearch.com/diabetic-neuropathy-market.html
  • Diabetic Foot Ulcers and Pressure Ulcers Market:    https://www.transparencymarketresearch.com/diabetic-foot-ulcers-pressure-ulcers-market.html

About Us 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact 

Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Research Blog: https://theglobalhealthnews.com/

SOURCE Transparency Market Research



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store